Literature DB >> 9788935

Voltage-dependent calcium release in human malignant hyperthermia muscle fibers.

A Struk1, F Lehmann-Horn, W Melzer.   

Abstract

Malignant hyperthermia (MH) results from a defect of calcium release control in skeletal muscle that is often caused by point mutations in the ryanodine receptor gene (RYR1). In malignant hyperthermia-susceptible (MHS) muscle, calcium release responds more sensitively to drugs such as halothane and caffeine. In addition, experiments on the porcine homolog of malignant hyperthermia (mutation Arg615Cys in RYR1) indicated a higher sensitivity to membrane depolarization. Here, we investigated depolarization-dependent calcium release under voltage clamp conditions in human MHS muscle. Segments of muscle fibers dissected from biopsies of the vastus lateralis muscle of MHN (malignant hyperthermia negative) and MHS subjects were voltage-clamped in a double vaseline gap system. Free calcium was determined with the fluorescent indicator fura-2 and converted to an estimate of the rate of SR calcium release. Both MHN and MHS fibers showed an initial peak of the release rate, a subsequent decline, and rapid turn-off after repolarization. Neither the kinetics nor the voltage dependence of calcium release showed significant deviations from controls, but the average maximal peak rate of release was about threefold larger in MHS fibers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788935      PMCID: PMC1299914          DOI: 10.1016/S0006-3495(98)77684-2

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  37 in total

Review 1.  Molecular pathophysiology of voltage-gated ion channels.

Authors:  F Lehmann-Horn; R Rüdel
Journal:  Rev Physiol Biochem Pharmacol       Date:  1996       Impact factor: 5.545

2.  Reduced Mg2+ inhibition of Ca2+ release in muscle fibers of pigs susceptible to malignant hyperthermia.

Authors:  V J Owen; N L Taske; G D Lamb
Journal:  Am J Physiol       Date:  1997-01

3.  Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle.

Authors:  M Richter; L Schleithoff; T Deufel; F Lehmann-Horn; A Herrmann-Frank
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

4.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

5.  Measurement and modification of free calcium transients in frog skeletal muscle fibres by a metallochromic indicator dye.

Authors:  L Kovacs; E Rios; M F Schneider
Journal:  J Physiol       Date:  1983-10       Impact factor: 5.182

6.  Time course of calcium release and removal in skeletal muscle fibers.

Authors:  W Melzer; E Rios; M F Schneider
Journal:  Biophys J       Date:  1984-03       Impact factor: 4.033

7.  Activation of Ca2+ release by caffeine and voltage in frog skeletal muscle.

Authors:  N Shirokova; E Ríos
Journal:  J Physiol       Date:  1996-06-01       Impact factor: 5.182

8.  Reduced inhibitory effect of Mg2+ on ryanodine receptor-Ca2+ release channels in malignant hyperthermia.

Authors:  D R Laver; V J Owen; P R Junankar; N L Taske; A F Dulhunty; G D Lamb
Journal:  Biophys J       Date:  1997-10       Impact factor: 4.033

9.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

10.  Sarcoplasmic reticulum calcium release in frog skeletal muscle fibres estimated from Arsenazo III calcium transients.

Authors:  S M Baylor; W K Chandler; M W Marshall
Journal:  J Physiol       Date:  1983-11       Impact factor: 5.182

View more
  8 in total

1.  CaATP prolongs strong actomyosin binding and promotes futile myosin stroke.

Authors:  Jinghua Ge; Akhil Gargey; Irina V Nesmelova; Yuri E Nesmelov
Journal:  J Muscle Res Cell Motil       Date:  2019-09-25       Impact factor: 2.698

2.  ATP utilization for calcium uptake and force production in different types of human skeletal muscle fibres.

Authors:  P Szentesi; R Zaremba; W van Mechelen; G J Stienen
Journal:  J Physiol       Date:  2001-03-01       Impact factor: 5.182

3.  [Telephone enquiries on the topic of malignant hyperthermia: Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig].

Authors:  B Petersen; T Busch; C-D Meinecke; B Börge; K Kluba; U X Kaisers; H Rüffert
Journal:  Anaesthesist       Date:  2015-10-19       Impact factor: 1.041

4.  Defects in Ca2+ release associated with local expression of pathological ryanodine receptors in mouse muscle fibres.

Authors:  Romain Lefebvre; Claude Legrand; Estela González-Rodríguez; Linda Groom; Robert T Dirksen; Vincent Jacquemond
Journal:  J Physiol       Date:  2011-10-03       Impact factor: 5.182

Review 5.  Management of malignant hyperthermia: diagnosis and treatment.

Authors:  Daniel Schneiderbanger; Stephan Johannsen; Norbert Roewer; Frank Schuster
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

6.  Action potential-evoked calcium release is impaired in single skeletal muscle fibers from heart failure patients.

Authors:  Marino DiFranco; Marbella Quiñonez; Perry Shieh; Gregg C Fonarow; Daniel Cruz; Mario C Deng; Julio L Vergara; Holly R Middlekauff
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

Review 7.  Calcium-induced release of calcium in muscle: 50 years of work and the emerging consensus.

Authors:  Eduardo Ríos
Journal:  J Gen Physiol       Date:  2018-03-07       Impact factor: 4.086

8.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.